BIO-Europe Spring 2019: Adrenomed’s Hein On Sepsis And Beyond
Executive Summary
Adrenomed’s chief business officer Frauke Hein explained to Mike Ward how the company has moved from establishing a diagnostic marker for septic shock to developing a therapeutic candidate.
You may also be interested in...
Wellington Partners Maintains Medtech Interests With New €210M Eurocentric Fund WPLS-V
While other venture capitalists are curbing their efforts in medtech, Wellington Partners intends to maintain its support for the sector earmarking about half of its new €210m WPLS-V fund for European medtech opportunities.
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Abalos Raises €12M Series A To Develop Arenavirus-Based Cancer Therapies
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.